# Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

> **NCT00303381** · PHASE2 · COMPLETED · sponsor: **EMD Serono** · enrollment: 194 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Interferon-beta-1a, 44 microgram
- **DRUG:** Placebo
- **DRUG:** Interferon-beta-1a, 66 microgram

## Key facts

- **NCT ID:** NCT00303381
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2003-01
- **Final completion:** 2003-01
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2013-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303381, "Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00303381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*